Endometrial Cancer

For a woman with complete resection of serous intraepithelial carcinoma of the endometrium, would you recommend adjuvant radiation or chemotherapy? Wh...

1 Answer available

What do you view as the future role for the combination of durvalumab + olaparib + chemotherapy in the management of patients with advanced/recurrent endometrial cancer following the DUO-E trial results?

Are there certain patient subgroups for whom you would use the IO+PARPi? Is there data from DUO-E regarding BRCA status and its potential impact on ...

2 Answers available

Would you recommend radiation for micrometastasis on sentinel lymph node biopsy in otherwise low risk endometrial cancer?

2 Answers available

How do you classify extensive LVSI in endometrial cancer?

In the PORTEC LVSI grading system, 3 or more vessel are classified as extensive LVSI, while the FIGO 2023 Endometrial Cancer staging they reference WH...

1 Answer available

In light of the improved outcomes seen in patients receiving IO +/- olaparib, what role, if any, do you think pelvic radiation still plays in the management of patients with advanced endometrial cancer?

3 Answers available

How would you manage a patient with FIGO 2018 IA G3 endometrioid adenocarcinoma with substantial LVSI, and was N- with adequate nodal staging?

Would you consider VBT alone vs EBRT and/or offer chemo? This is a female in her late 60s with FIGO 2023 IIB disease given substantial LVSI+ (>5 v...

4 Answers available

Would you consider offering immunotherapy +/- olaparib to a patient with early-stage endometrial carcinoma for whom you are recommending adjuvant chemotherapy based on improved outcomes seen in RUBY/DUO-E/NRG-GY018?

If yes, would you apply this broadly or reserve the addition of IO to chemotherapy for patients with high-risk histologies (e.g., carcinosarcoma) or o...

2 Answers available

In a patient with HER2+ advanced endometrial cancer, do you include IO(+/- olaparib) in their treatment regimen, or only trastuzumab in addition to carboplatin/paclitaxel?

Does your decision depend on MMR status? Would you use the same approach for neoadjuvant treatment?In light of relevant trials including RUBY, GY018, ...

3 Answers available

Would you recommend adjuvant chemo+IO +/- olaparib for patients with occult stage III disease identified after staging surgery with no measurable residual disease?

DUO-E, GY-018, and RUBY included patients with stage III and IV endometrial cancer WITH measurable disease.Would your decision change based on the mis...

4 Answers available

For patients with advanced endometrial cancer, are the improved outcomes in PFS from DUO-E/RUBY/NRG-GY018 sufficient to move immunotherapy to the frontline for all presuming FDA approval?

Are there patients for whom you would still reserve IO for salvage/recurrent setting (eg IO + lenvatinib)? Would you base this on MMR status or other ...

2 Answers available

In light of new NCCN guidelines that state combination chemotherapy + pelvic RT should be reserved for endometrial cancer of at least stage IIIB, will you recommend EBRT in addition to chemotherapy for stage IIIA endometrial cancers?

1 Answer available

Do you follow GOG, ASTRO, or PORTEC recommendations for adjuvant therapy in stage I endometrial cancer patients?

What would you recommend for a patient in their 60s with stage IB grade 1 endometrial cancer without LVSI? How would this differ for a patient with st...

6 Answers available

Despite the paucity of strong data showing benefit of chemotherapy + radiotherapy in patients with stage I-II high risk histology endometrial cancer, if you recommend treatment with both modalities, how do you determine treatment schedule?

Do you proceed with sequential, concurrent, or sandwich treatment?

4 Answers available

What are your top takeaways from SGO 2023?

7 Answers available

For a medically inoperable clinically-staged FIGO IA endometrial cancer with serous, clear cell or other non-endometrioid, high-risk histology treated with EBRT alone, would you cover elective lymph nodes, or treat the uterus alone?

The patient also declines any brachytherapy treatment.

2 Answers available

What dose and target volume do you use for neoadjuvant chemoRT in a patient with a locally advanced uterine/endometrial cancer involving parametria, cervix, and the uterine fundus (no side wall involvement) requiring downstage to be eligible for surgery?

Her primary disease is too large for any brachytherapy; if substantial residual disease remains, how would you approach external beam boost?

2 Answers available

Do you include trastuzumab in the treatment regimen of patients with advanced stage HER2+ endometrial cancer that is NOT serous or carcinosarcoma?

1 Answer available

When, if ever, would you perform Her2 testing in serous intraepithelial neoplasia of the endometrium?

1 Answer available

When do you expect the 2023 FIGO staging for endometrial cancer to become adopted clinically in the US?

How will you translate treatment recommendations from older studies to the new staging system?

3 Answers available

In mismatch repair deficient recurrent endometrial cancer eligible for single agent PD-1 inhibitor, do you prefer pembrolizumab or dostarlimab and why?

1 Answer available

For a patient with IIIC endometrial adenocarcinoma diagnosed and treated with 6 cycles of Carboplatin/Paclitaxel two years prior, would you consider maintenance therapy with PD-L1 inhibition, given results of GY018 and RUBY?

2 Answers available

Is it ever acceptable to treat low pelvis (vs. whole pelvis) for an early vaginal recurrence of endometrial cancer?

A patient in her 70s initially underwent TAHBSO + LNB with Stage I, G1 cancer, No LVSI. 18 months later with very small mucosal recurrence (5mm). HDR ...

3 Answers available

In patients with advanced endometrial cancer who you plan to treat with chemotherapy + immunotherapy (per GY018 or RUBY), how and when do you utilize adjuvant EBRT and/or brachytherapy?

Does the presence of parametrial or cervical involvement impact your decision? How do you sequence treatment modalities?

3 Answers available

How would you manage a Stage IB endometrioid endometrial cancer, status post staging surgery, with a rapid vaginal recurrence <1 month post operatively?

This case involves an impressive ‘high volume’ vaginal recurrence and patient was not originally planned for adjuvant therapy. Concerned t...

2 Answers available

Would you offer pelvic radiation in a patient with Stage IIIC endometrial cancer who has Crohn's disease and a permanent ileostomy?

Would the extent of nodal involvement sway you one way or another (i.e., a micromet in a single sentinel node)?

2 Answers available

When treating endometrial cancer patients with a combination of chemotherapy and vaginal cuff brachytherapy, when do you deliver cuff brachy?

Do you wait until chemotherapy completion, interdigitate between cycles 1-2 only when feasible, or between any cycle of chemotherapy? What factors wo...

2 Answers available

What, if any, adjuvant treatment do you offer a a patient with stage I clear cell endometrial carcinoma?

1 Answer available

What is the optimal interval between vaginal cuff brachytherapy sessions?

At our institution we often give 5.5 Gy x 4 fractions. There really does not appear to be a general consensus regarding timing. Interested in what oth...

5 Answers available

For patients with endometrial cancer, should tumor size be included as a risk factor for recurrence?

2 Answers available

What is your approach to management of chronic neutropenia in a patient with Sjogren’s who was recently diagnosed with metastatic endometrial cancer and plans to start chemotherapy?

ANC <500

1 Answer available

Does the path length of vaginal cuff cylinder brachytherapy treatment as adjuvant therapy for endometrial cancer vary based on histology (serous, etc)?

4 Answers available

Do you add pelvic RT for stage II gr 2 endometrial cancers with multiple high risk features?

Would there be a survival advantage to pelvis RT with deep myometrial invasion, LVSI and ITC?

3 Answers available

Would you recommend adjuvant chemotherapy to a patient who has stage IB grade 1 endometrioid endometrial cancer with isolated tumor cells in two pelvic lymph nodes and extensive LVSI?

1 Answer available

What is your preferred adjuvant treatment for surgically staged IB dedifferentiated endometrial carcinoma, with negative SLNBx and extensive LVSI?

Would you consider chemoRT or carbo/taxol/immunotherapy?

2 Answers available

How do you approach the adjuvant treatment for grade 1 endometrial cancer with micrometastasis in a sentinel lymph node if the tumor is otherwise low risk?

In what scenarios would you consider observation versus alternative adjuvant treatment modalities?

2 Answers available

What are your image guidance instructions for post-op endometrial cancer EBRT?

What instructions do you give your radiation therapists - do you rely on OAR identification (ie. bladder and rectum filling) or soft tissue match to t...

5 Answers available

How do you manage early stage uterine carcinosarcoma?

Do you give cuff and chemo or pelvic CRT or chemo alone?

3 Answers available

How would you manage a patient in her 50s with FIGO IA clear cell carcinoma of the endometrium with extensive LVSI and ITCs in an obturator node after 6 cycles of carbo/taxol?

Would you offer pelvic RT or intracavitary brachytherapy?

7 Answers available

How should molecular studies, in particular the presence of POLE or p53 mutations, be incorporated into the decision to treat an "intermediate risk" endometrial cancer patient with adjuvant therapy after hysterectomy?

Considering the ASTRO guidelines recommend against systemic therapy for patients with FIGO stage I-II endometrioid adenocarcinoma, would your recommen...

6 Answers available

What are your top takeaways in Gynecologic Cancers from ASCO 2023?

4 Answers available

Given patients with substantial LVSI experience a pelvic recurrence rate of ~25%, how do you counsel patients with stage IA endometrioid endometrial cancer with LVSI regarding the relative risks/benefits of EBRT versus VBT alone?

Please comment on toxicity profiles and the insufficient evidence regarding overall survival.

5 Answers available

How do you manage a patient with an endocervical cancer indeterminate for endometrial or cervical origin status post TAH/BSO and sentinel node biopsy?

The patient is >40 yo with Lynch syndrome and a history of endometrial hyperplasia status post R0 TAH/BSO with SLNBx for a 5.2 cm, grade 3 adenocar...

3 Answers available

How do you manage a distal vaginal recurrence of endometrial adenocarcinoma in a patient who had adjuvant external beam and cylinder brachytherapy boost to the top 4 cm of the vaginal cuff?

The recurrence is mucosal and inferior to the prior field.

1 Answer available

In a fit/young patient, how do you manage endometrial cancer with inguinal node involvement that has had favorable response after upfront systemic therapy?

Surgery remains an option. Given favorable response, would you recommend pre-op or definitive RT +/- chemo?

1 Answer available

What is your preferred first line systemic treatment for recurrent, metastatic, low grade, ER/PR+ pMMR endometrioid endometrial carcinoma?

3 Answers available

Would you consider chemoradiation + chemotherapy as in PORTEC-3 regimen for p53 mutated stage IA endometrial cancer, though this trial did not include those with stage IA disease?

If you do not use the PORTEC-3 regimen for p53 mutated IA endometrial cancer, what specific protocol or combination of chemotherapy and radiation ther...

5 Answers available

What is your approach to the adjuvant treatment of early-stage mixed-histology endometrial cancer with a significant clear-cell component?

How do you take into account pathologic factors like %clear cell histology, myometrial invasion, and LVSI?

3 Answers available

Do you add trastuzumab to adjuvant chemotherapy for patients with Her2+ stage I-II high grade serous uterine cancer following surgical staging?

Or would you reserve its use to stage III-IV or recurrent disease (as in Fader et al., PMID 29584549)?

1 Answer available

Do you give vaginal cuff brachytherapy and/or whole pelvis, for patients with Stage III endometrial adenocarcinoma?

5 Answers available

What uterine risk factors do you consider when recommending VBT boost after EBRT?

Would you recommend if there is only one uterine factor or do you typically require multiple to make this recommendation?

4 Answers available

When, if ever, would you offer adjuvant radiation to a patient with stage IVB endometrial cancer following neoadjuvant chemotherapy and cytoreductive surgery?

Please consider this National Cancer Database (NCDB) and Surveillance, Epidemiology, and End Results Program (SEER) registry study (Barrington et al.,...

2 Answers available

If a patient with MSI-H endometrial cancer slowly progresses on single-agent pembrolizumab, would you add lenvatinib?

1 Answer available

For patients with endometrial recurrence of vaginal vault/pelvis, who are not candidates for brachytherapy boost, what external beam boost dose have you used following pelvic EBRT?

1 Answer available

What is your adjuvant therapy approach for stage II endometrioid endometrial cancer?

1 Answer available

How would you treat a recurrent endometrial cancer at the vaginal cuff that was initially FIGO 1A with no adj treatment, in a patient with actively treated scleroderma?

3 Answers available

How do you treat endometrial cancer in the setting of a pCR after neoadjuvant chemotherapy?

Female in her 60s who had presented originally with well-differentiated endometrioid adeno clinically and radiographically involving bilateral paramet...

1 Answer available

What is your approach to the adjuvant treatment for stage IA grade 2 endometrioid adenocarcinoma without LVSI whose molecular classification is p53 abnormal (MMR intact, POLE wild type)?

How does your approach differ for patients under age 60, between 60-70, and over age 70?

1 Answer available

How would you manage recurrent endometrial cancer limited to pelvic and inguinal nodes in a patient with no previous radiation?

1 Answer available

How would you treat an isolated para-aortic lymph node endometrial cancer recurrence following a prolonged disease free interval previously treated with surgery, chemotherapy, and radiation therapy, if it is located outside of the previously irradiated field?

How does histology and/or molecular testing change your approach? How does the length of the disease free interval change your approach?

1 Answer available

How would you treat completed resected rectosigmoid recurrence of endometrial adenocarcinoma?

This patient previously received hysterectomy with adjuvant vaginal cuff brachytherapy without pelvic RT. Colonoscopy demonstrated invasive disease, b...

2 Answers available

If metastatic disease is found at the time of minimally invasive hysterectomy for uterine cancer, when would you decide to convert to open versus minimally invasive debulking?

1 Answer available

What would you recommend in the adjuvant settings for an elderly patient status post hysterectomy without nodal staging and was found with FIGO 1A, G3 endometrial cancer, with no LVSI and no myometrial involvement, without nodal staging?

This endometrial cancer was a fortuitous finding following vaginal hysterectomy.

1 Answer available

What is the best method for ensuring that vaginal cuff cylinder is in proper position at each fraction?

3 Answers available

What is your approach to an incidental diagnosis of low risk endometrial cancer in a patient who underwent minimally invasive hysterectomy with uterine morcellation with gross intra-operative tumor spillage?

1 Answer available

How do you approach systemic treatment for endometrial endometrioid adenocarcinoma with neuroendocrine differentiation?

In what situations would you use a neuroendocrine chemotherapy regimen over carboplatin+paclitaxel?

2 Answers available

When, if ever, would you consider ovarian preservation in a premenopausal patient with high grade endometrial carcinoma?

If the patient was interested in fertility preservation would you recommend oocyte preservation before or after hysterectomy - or not at all?

1 Answer available

Do you offer patients with advanced endometrial cancer lower starting doses of lenvatinib when used in combination with pembrolizumab given high adverse event rates with 20 mg daily?

Is there a role for using pembrolizumab alone in microsatellite stable endometrial cancer if patients are unable to tolerate lenvatinib?

3 Answers available

What are real world exclusion criteria for the use of lenvatinib + pembrolizumab for advanced endometrial cancer?

Are there specific clinical or social scenarios that would preclude the use of this treatment?

2 Answers available

Is there a difference in survival or disease response between patients with recurrence free interval ≥1 vs <1 year from platinum-based cytotoxic therapy who are treated with pembrolizumab + lenvatinib?

In the KEYNOTE-775 study, what was the proportion of patients who had a recurrence free interval ≥1 year from platinum-based cytotoxic chemotherapy...

1 Answer available

Are there any data that suggest superiority of lenvatinib + pembrolizumab vs platinum-based cytotoxic chemotherapy for advanced or recurrent endometrial cancer?

Are there any planned trials to compare lenvatinib + pembrolizumab and platinum-based cytotoxic chemotherapy for advanced or recurrent endometrial can...

1 Answer available

How do you approach adjuvant chemotherapy for high risk/advanced endometrial cancer patients?

Does your approach to the number of cycles vary based on plan to include radiation therapy or presence of certain histopathologic features?

1 Answer available

Is there a difference in the incidence of serious immune-related adverse events with the lenvatinib + pembrolizumab combination vs pembrolizumab alone in endometrial cancer?

Anecdotally, I have seen more serious IRAEs in patients I'm treating with this regimen than anticipated. Is there higher risk with this drug combinati...

3 Answers available

Would you include a seroma in an adjuvant radiation field for post-op endometrial cancer?

Is there any particular reason to include or not include this in the treatment volumes?

3 Answers available

How would you manage an isolated port-site recurrence of grade 1 endometrioid endometrial cancer?

If resected, what is your approach to adjuvant therapy?

1 Answer available

How do positive pelvic washings influence your decision to administer adjuvant therapy to early stage endometrial cancer who otherwise meets no criteria for adjuvant therapy?

<60y/o, grade 1 endometrioid endometrial cancer. TLH, BSO, sentinel nodes. Stage IA, focal LVSI, 20% myometrial invasion, negative sentinel nodes, ...

2 Answers available

How would you manage a bulky, locally advanced endometrial cancer with extensive parametrial involvement in a patient inoperable due to medical comorbidities?

3 Answers available

When, if ever, would you consider lenvatinib + pembrolizumab as first line therapy for patients with stage IV microsatellite stable endometrial cancer?

Are there certain patient or disease related factors that would lead you to incorporate lenvatinib + pembrolizumab earlier?

1 Answer available

Is there a role for progestin therapy to temporize bleeding from endometrial cancer in a patient with an active venous thromboembolism?

1 Answer available

What is optimal therapy for a 5 year delayed recurrence of uterine cancer, rendered NED by solitary pulmonary metastasis resection?

And if the tumor is MSI-H, does that alter your thoughts?

3 Answers available

Do you routinely check tumor genomics, including POLE status for new endometrial cancers?

How does the presence of specific mutations affect your adjuvant treatment planning or patient counseling? Given POLE mutation status can currently o...

1 Answer available

In which circumstances would you offer adjuvant brachytherapy to a surgically staged patient with endometrial cancer if they have received prior pelvic external beam radiation therapy for a non-gynecologic pelvic tumor?

1 Answer available

If a patient with HER2+ uterine serous carcinoma recurs while on maintenance trastuzumab, would you continue trastuzumab with second line chemotherapy?

Given data from metastatic breast cancer trials that show benefit with continuing trastuzumab despite progression.

2 Answers available

Is adjuvant treatment recommend for a 0.8cm serous endometrial CA confined to polyp s/p hysterectomy + surgical staging?

2 Answers available

In patients with recurrent MSI-H endometrial cancer on immunotherapy with pembrolizumab, when do you discontinue therapy?

Do you stop therapy at 2 years or continue until progression of disease?

1 Answer available

How would you counsel a patient with incidental diagnosis of at least high intermediate risk endometrial cancer, found on robotic hysterectomy with non-contained uterine morcellation and no node sampling?

Path significant for LVSI and MELF pattern. Post-operative CT negative for metastatic disease.

1 Answer available

Do you modify your treatment for a patient with ulcerative colitis needing vaginal brachytherapy?

2 Answers available

Would you offer adjuvant RT to a FIGO IV endometrial CA with pulm mets s/p hysterectomy with residual disease, then cCR to both sites after chemotherapy?

1 Answer available

How do you manage a cT3bN0 endometrial cancer with large vaginal drop met s/p NAC and TAH/BSO with pCR?

Would you recommend whole pelvis as well as vaginal cuff brachytherapy?

1 Answer available

What is your adjuvant therapy for node positive, low grade endometrioid endometrial adenocarcinoma?

3 Answers available

How do you manage early stage I uterine serous carcinoma?

VC brachy, pelvic RT, +/- chemo? Does your management change if it is confined to the endometrium without myometrium invasion or if it is only ...

3 Answers available

How do you treat a Stage II Grade 3 endometrioid endometrial adenocarcinoma?

1 Answer available

Do you treat an endometrial cancer that is microsatellite-stable but has a high TMB after progressing on platinum-based therapy with pembrolizumab?

2 Answers available

Would you offer adjuvant radiation in addition to chemotherapy for a patient with stage IIIC uterine carcinosarcoma with cervical involvement?

2 Answers available

How do you approach a patient with recurrent endometrial cancer within the field of prior primary radiation who is not a surgical or cytotoxic chemotherapy candidate?

1 Answer available

In patients diagnosed with endometrial cancer who do not undergo SLNB or LND at the time of hysterectomy, what criteria is used to recommend completion surgery for LN assessment?

2 Answers available

What is your preferred surgical management of an endometrial cancer with clinically apparent extension to the cervix?

No parametrial involvement on MRI.

2 Answers available

Would you recommend adjuvant therapy for a non-invasive Grade 3 endometrioid endometrial cancer that is P53 wild-type and MMR deficient (due to methylation)?

1 Answer available

What is the longest acceptable interval between hysterectomy and vaginal cuff brachytherapy for high/intermediate risk endometrial cancer in the age of COVID-19?

2 Answers available

When do you include the presacral nodes in post-operative XRT of endometrial cancer?

Would involvement of the PA nodes be an indication?

1 Answer available

With vaginal cuff brachytherapy, do you treat to the surface or a depth and why?

1 Answer available

How would you proceed with the management of a healthy patient with stage IV grade 3 endometrioid uterine cancer metastatic to the right diaphragm and other peritoneal surfaces?

No mesenteric/small bowel/lesser sac involvement on imaging

1 Answer available

How do you approach a medically inoperable patient with clinically stage 2 grade 1 endometrioid endometrial carcinoma with heavy vaginal bleeding that is refractory to EBRT and requiring inpatient management with transfusions?

1 Answer available

What HDR dosing would you use in the neoadjuvant setting of endometrial cancer?

1 Answer available

How would you treat a patient with pT1bN0 G1 endometrioid carcinoma with significant MMI (~80%) and +LVSI?

EBRT vs VB? She technically meets PORTEC2, but also meets GOG99 and GOG249 (for pelvic RT) and PORTEC4. NCCN recommends for IB grade 1 vaginal brachyt...

2 Answers available

What are indications to add WPRT +/- PA field to chemotherapy for uterine serous carcinoma?

2 Answers available

Is there a role for elective para-aortic nodal irradiation in endometrial cancer?

Is there any indication for ENI in early stage disease or in advanced stages, without pathologic confirmation or PET positivity or CT size criteria?

1 Answer available

Would you consider maintenance therapy in a recurrent endometrial cancer that is MSI-H and ER/PR+ that achieved a complete response after pelvic RTx and 4 cycles of Carbo/Taxol?

1 Answer available

How would you manage an elderly but otherwise healthy patient with a high grade endometrioid uterine cancer with micro metastasis to a SLN, but otherwise confined to the uterus with superficial myometrial invasion?

2 Answers available

How would you approach second isolated vaginal cuff recurrence in a young patient with FIGO IA Grade 2 endometrioid endometrial adenocarcinoma who received EBRT+ interstitial brachy for her initial recurrence?

The patient was initially observed after radical hysterectomy due to young age, FIGO IA grade 2 disease. The patient had isolated, biopsy-proven vagi...

3 Answers available

Would you offer consolidative radiation for oligometastatic uterine serous CA s/p surgery and chemotherapy with complete response?

1 Answer available

How do you plan for excess nonconforming vaginal tissue with a HDR cylinder?

In women receiving HDR intracavitary brachytherapy to treat the vaginal cuff, how do you overcome the challenge of excess lateral vaginal tissue ("dog...

3 Answers available

Do you recommend adjuvant treatment for nodal isolated tumor cells in an otherwise low-risk endometrial cancer?

1 Answer available

How would you approach adjuvant therapy for a IIIC2, FIGO grade 2, endometrial cancer with 1/7 positive (para-aortic) lymph nodes?

PET- CT before surgery visualised a tumor localised to the uterus and a PET positive 3 cm enlarged node at L3 level. Final path: endometroid FI...

1 Answer available

How would you deliver/time radiation for a patient with IIIC1 serous endometrial cancer who is HER2+?

Planning carboplatin/taxol/trastuzumab. Cervical stromal invasion on path. Looking for pelvic vs brachy and timing with chemotherapy.

1 Answer available

How would your follow-up change for a patient, non-surgical candidate, with endometrial cancer treated with definitive radiation?

2 Answers available

Do you recommend sentinel lymph node dissection or full lymphadenectomy for high grade and type II uterine cancers?

1 Answer available

What normal tissue constraints do you use, if any, in patients receiving vaginal cuff brachytherapy alone?

2 Answers available

What adjuvant therapy do you recommend for comprehensively staged, stage II, FIGO grade 3 deeply invasive endometrial cancer?

1 Answer available

How would you treat a stage IA mixed carcinosarcoma/neuroendocrine tumor of the endometrium, negative LNs?

6.6cm tumor, 15% MI

1 Answer available

How would you manage a clinically inoperable, stage IIIB, MMR deficient uterine cancer?

Tumor felt to be technically unresectable due to extensive cervical/parametrial involvement. ER/PR and HER2 testing are pending.

1 Answer available

Would uterine serosal involvement change your adjuvant treatment recommendation for a patient with Stage II grade 2 endometrial cancer?

Tumor traverses the myometrium to focally involve the serosa; 1/6 sentinels with ITC and the rest negative.

2 Answers available

If a patient with recurrent endometrial cancer experiences minimal or slow disease progression on pembrolizumab or pembro/lenvatinib, would you consider continuing or would you change agents?

Patient has tolerated combination therapy well to date.

1 Answer available

How does number of ITC influence your approach to adjuvant RT for a surgically staged 1B endometrial cancer meeting HIR criteria?

Pt is 73yo, Grade 1, 81% invasion, MELF like features, foci of LVSI, and 47 ITCs identified.

3 Answers available

Do you recommend adjuvant therapy for early stage (IB) high grade endometrial stromal sarcoma?

1 Answer available

How would you sequence chemotherapy and radiotherapy for a patient with stage IIIC1 serous endometrial carcinoma?

HER2 status is pending

2 Answers available

Would you change your approach to adjuvant radiation for an incompletely staged, at least IB, grade 1 endometrial cancer, if a uterine perforation occurred at time of surgery?

Pt is 69yo, tumor 1.4cm, negative LVSI, ER/PR +

5 Answers available

How does positive p53 staining influence your recommendation for adjuvant therapy in comprehensively staged early (stage IA or IB), grade 2, endometrioid endometrial cancers?

If patient meets high intermediate risk criteria, would you consider chemotherapy in addition to radiation?

1 Answer available

Would the presence of multifocal LVSI change your adjuvant treatment recommendation for a surgically staged IA dedifferentiated endometrial carcinoma?

Does not technically meet high intermediate risk criteria.

2 Answers available

Outside of a clinical trial, do you currently incorporate the TCGA molecular classification into management decisions for patients with endometrial cancer?

2 Answers available

How do you counsel patients regarding adjuvant therapy for stage IA uterine serous carcinoma confined to a polyp?

2 Answers available

How would you deliver pelvic radiation as cost-efficiently as possible for a patient with endometrial cancer?

In the unfortunate setting where you cannot get an underinsured patient whose policy does not cover radiotherapy started on treatment without guarante...

2 Answers available

How would the presence of micro-metastatic disease in multiple sentinel pelvic lymph nodes change your recommendation for adjuvant therapy in a patient with otherwise stage I endometrioid adenocarcinoma?

1 Answer available

For a recurrent, MSI-H endometrial cancer, do you usually treat with Pembrolizumab alone or in combination with Lenvatinib?

1 Answer available

Would development of a rectovaginal fistula mid-treatment with second line pembrolizumab/lenvatinib for endometrial cancer cause you to change regimens, eliminate lenvatinib, or continue current therapy?

The patient has a history of pelvic radiation and progressed through first line carboplatin/taxol. She has had a partial response to pembro/lenvatinib...

1 Answer available

How do you sequence chemotherapy with radiotherapy for advanced endometrial cancer?

4 Answers available

Would you consider staging lymph node dissection for a patient referred for stage IA endometrial cancer and MELF pattern on final pathology?

Incidental diagnosis after hysterectomy

2 Answers available

Would you recommend adjuvant therapy for a 1A grade 2 endometrial adenocarcinoma with MELF pattern, and ITCs in one pelvic lymph node?

1 Answer available

How does sarcomatous overgrowth in a uterine carcinosarcoma change your management of adjuvant therapies?

1 Answer available

What adjuvant therapy would you offer a patient with Stage II uterine serous carcinoma without lymph node sampling?

3 Answers available

When would you add a vaginal cuff brachy boost to external beam radiation for uterine carcinosarcoma?

Would you offer EBRT alone or EBRT with vaginal cuff brachytherapy after surgery and chemotherapy for stage III (T3N0) carcinosarcoma of the uterus? ...

1 Answer available

How do you counsel patients with BRCA-1 mutations regarding the role of hysterectomy as a part of risk-reducing surgery?

2 Answers available

Would you offer adjuvant therapy following successful resection of a solitary lung recurrence of leiomyosarcoma if no other evidence of recurrent disease on PET CT?

1 Answer available

What starting dose of lenvatinib are you ultilizing in recurrent endometrial cancer patients initiating lenvatinib/pembro?

1 Answer available

Would you recommend systemic therapy in a patient with a history of Stage III high grade serous endometrial cancer s/p resection of a solitary pulmonary metastasis after a long disease free interval?

Does residual grade 1-2 neuropathy from Taxol/ carbo 10 years ago affect your recommendation?

2 Answers available

Which tumor markers, if any, would you use to follow patients with high grade or advanced endometrial cancers?

2 Answers available

Do you recommend concurrent chemotherapy with XRT for inoperable patients with stage I-II high-risk endometrial carcinoma?

Ie for patients who are inoperable due to comorbidities?

2 Answers available

Do you offer pelvic radiation for endometrial cancer with ITCs in the node(s) and no other high or intermediate risk factors?

1 Answer available

What adjuvant therapy would you offer a fully resected isolated pelvic peritoneal recurrence of a uterine serous carcinoma?

1 Answer available

What dose is needed for salvage RT for recurrent endometrial cancer in untreated PA region (who has received pelvic RT) after good PET response to systemic therapy?

For a patient with good response to immunotherapy (unable to receive chemotherapy due to kidney function, comorbidities) where previously avid LN have...

1 Answer available

Is there any benefit to giving pelvic radiation prior to systemic chemotherapy or vice versa for a patient with stage IIIA uterine serous carcinoma?

HER2 positive

1 Answer available

Would you recommend maintenance therapy with a PARP inhibitor for BRCA+ patients with advanced uterine serous cancer?

Since no data exists or is pending, and the two disease processes are similar, should we consider PARP inhibition in this setting? This is assumi...

1 Answer available

Do PORTEC-3 and GOG-258 change your approach to managing patients with high-risk or node positive endometrial cancer?

http://abstracts.asco.org/199/AbstView_199_180760.html http://abstracts.asco.org/199/AbstView_199_187537.html

3 Answers available

Would you consider pembrolizumab plus lenvatinib for stage IV uterine carcinosarcoma after progression on chemotherapy as per Keynote-146 and now with Keynote-775?

Keynote-146 included 9 (17%) "other adenocarcinomas," but did not specifically exclude carcinosarcoma. Carcinosarcoma was specifically excluded from K...

1 Answer available

Do you offer vaginal cuff brachy alone, vaginal cuff brachy and chemo, or WPRT for surgically staged IB grade 3 endometrial cancer?

Does the GOG 249 abstract guide you one way or the other?

3 Answers available

For a patient with recurrent endometrial cancer involving the vagina with a good response to EBRT (<5mm residual), how would you prescribe adjuvant brachytherapy with a cylinder to the entire vaginal length?

2 Answers available

How successful is IVF after definitive radiation therapy to the pelvis for endometrial cancer?

How do you counsel a pre-menopausal female with endometrioid cancer desiring definitive RT with egg harvesting and IVF for fertility preservation inst...

2 Answers available

Would you offer adjuvant chemotherapy in addition to pelvic RT in a patient with fully resected pelvic recurrence of endometrial carcinoma?

1 Answer available

What chemotherapy options are there for clear cell carcinoma of uterus with progression of disease on carboplatin and paclitaxel?

1 Answer available

With COVID-19 worries, are you more likely to offer women with endometrial cancer vaginal cuff brachytherapy over EBRT?

1 Answer available

In a patient metastatic recurrent endometrioid endometrial cancer who has a mixed response to carboplatin and paclitaxel, what is your next choice of therapy?

No adjuvant treatment was given upfront

1 Answer available

What is your process for obtaining and using next generation sequencing on patients with advanced endometrial cancer?

1 Answer available

In a patient with a vaginal cuff recurrence from endometrial cancer not amenable to interstitial brachytherapy, how would you boost after 45Gy?

Insurance authorization for protons is pending, but if the patient cannot have protons would you treat with standard fractionation to ~70Gy or conside...

1 Answer available

In a surgically staged Stage II Grade 1 endometrial adenocarcinoma, with no other high risk factors, would you treat with brachytherapy alone or add on the pelvic RT?

NCCN recommends brachytherapy plus or minus pelvic RT for surgically staged Grade 1, Stage II patients, but these originally staged IIB patients were ...

4 Answers available

Would you recommend radiotherapy for a para-aortic recurrence of endometrial cancer in a patient who previous completed surgery, chemotherapy, and WPRT?

1 Answer available

How does the presence of microcystic elongated and fragmented (MELF) invasion impact post operative treatment of Stage IA FIGO grade 1 endometrial cancer?

1 Answer available

How would you approach an inoperable, elderly, frail patient with high risk endometrial cancer?

1 Answer available

How would you treat an endometrial cancer with pelvic sidewall nodes, patient s/p TAH/BSO but nodes were fixed and unresectable?

Would you consider EBRT or brachytherapy boost to the nodes? what dose would you recommend?

2 Answers available

When do you use a vaginal cuff boost with pelvic RT for stage II endometrial cancer?

For the management of stage II endometrial cancer, NCCN says pelvic RT and/or vaginal brachytherapy. Do you ever add vaginal cuff boost to pelv...

3 Answers available

Does the presence of a POLE mutation in endometrial cancer guide your recommendations regarding adjuvant radiation?

1 Answer available

How would you approach a young patient with a locally advanced endometrial cancer with cervical involvement and a solitary bone metastasis?

2 Answers available

What alternative boost methods (techniques / dose) do you recommend for a vaginal cuff boost after whole pelvis when imaging shows bowel adherent to the vaginal cuff?

1 Answer available

Would the findings of a synchronous T1a ovarian endometrioid adenocarcinoma affect your treatment recommendation for a IB, G2 uterine endometrioid adenocarcinoma and LVSI?

2 Answers available

How do you treat a Stage I endometrial squamous cell carcinoma?

MRI and cervical biopsy are negative for cervical involvement

1 Answer available

Would focal clear cell features change your management for a grade 2 endometrial adenocarcinoma?

1 Answer available

For a patient with vaginal adhesions/stenosis, do you recommend any other therapy besides a dilator?

Would estrogen cream be helpful in this scenario?

1 Answer available

Do you continue Megestrol in a patient with inoperable endometrial cancer during definitive radiation therapy?

are there any positive or negative synergies from combined megestrol/RT treatment?

1 Answer available

Would uterine perforation at the time of hysterectomy push you to recommend pelvic RT in a patient who would otherwise receive cuff brachytherapy?

1 Answer available

Is obesity a risk factor for recurrence after definitive treatment for endometrial cancer?

At what point would you introduce the discussion of weight management, whether for risk reduction or overall health?

1 Answer available

How do you decide on adjuvant therapy in a patient with a Stage IA uterine carcinosarcoma without any myometrial invasion?

The NCCN recommends either systemic therapy + brachytherapy or pelvic RT + brachy or brachy alone or observation. How do you decide among these option...

1 Answer available

How would you treat a patient with a FIGO G1 pT1bN0 endometrial adenoCA involving the lower uterine segment with >50% invasion and a separate focus of disease found involving the endocervical mucosa with no cervical stromal invasion?

The disease involving the endocervix was felt to be separate and appeared like a drop metastases

1 Answer available

Are you using the new FIGO 2018 staging or waiting until it is incorporated into the next AJCC edition?

4 Answers available

Do you recommend stopping olaratumab in patients receiving doxorubicin/olaratumab for treatment of advanced sarcoma?

Given the recent press release regarding the update on the phase 3 soft tissue sarcoma study of LARTRUVO (olaratumab) showing no benefit to the combin...

1 Answer available

For a patient with carcinosarcoma of the uterus and an allergic reaction to paclitaxel, would you have any reservations about using docetaxel instead?

1 Answer available

What is the maximum time you would wait after hysterectomy to start RT for a FIGO II endometriod adenocarcinoma before cancelling treatment and saving for salvage?

1 Answer available

What factors do you use to determine whether to add brachytherapy to EBRT for IIIC endometrial cancer?

Current NCCN guidelines suggest that vaginal brachytherapy is optional, and there may be concern for over-treatment locally given competing risk of di...

3 Answers available

Do you have any normal tissue constraints for endometrial cancer patients receiving EBRT and vaginal cuff brachytherapy?

1 Answer available

Do you add chemotherapy to pelvic radiation and brachytherapy for an isolated vaginal cuff recurrence of endometrial cancer?

3 Answers available

Are there any situations in which you would offer brachytherapy alone instead of whole pelvis RT +/- brachytherapy for an endometrial cancer vaginal cuff recurrence?

2 Answers available

When do you offer observation for resected stage II endometrial cancer?

In what situations is it appropriate to offer observation (rather than VBT) to patients with stage II endometrial carcinoma who have had a radical hys...

1 Answer available

How would you manage a patient with low-volume non-invasive endometrioid carcinoma that is found in both the endometrium and ovary (pN0)?

Would you approach this situation as synchronous primaries (eg. FIGO IA in both) or as a locally advanced endometrial cancer (FIGO IIIA)? What adjuva...

2 Answers available

How would you approach the management of a patient with locally advanced cervical cancer as well as synchronous endometrial adenocarcinoma?

1 Answer available

What strategies have you found to be most helpful in improving patient compliance with vaginal dilator use after pelvic radiotherapy?

1 Answer available

Do you ever alter dose/fractionation for early stage endometrial cancer patients receiving vaginal brachytherapy alone?

And if so, in which situations do you offer differing doses?

1 Answer available

How does positive peritoneal washings factor into your treatment decisions regarding pelvic radiation and/or chemotherapy?

For example, in an otherwise intermediate risk localized endometrial cancer (Grade 2, FIGO IB)?

1 Answer available

How do you decide whether to treat proximal vs. entire vaginal cuff with intracavitary brachytherapy in early-stage endometrial adenocarcinoma?

What clinicopathologic features do you typically consider?

2 Answers available

What clinical and pathological factors guide your decision making when considering whether to recommend vaginal cuff brachytherapy following TAH/BSO for a FIGO stage IA or IB endometrial carcinoma?

2 Answers available

Would you include a lymphocele in your IMRT treatment volumes for endometrial carcinoma?

If the post-operative simulation films reveal a significant lymphocele secondary to pelvic lymph node sampling, is it imperative that the entire lymph...

1 Answer available

For which patients with stage IA nonsurgically staged endometriod cancer would you add pelvic RT?

The gyn oncs at my institution sometimes will not perform lymphadenectomy if biopsy indicates low risk disease. Would LVSI as sole adverse risk factor...

1 Answer available

What is the optimal management of a pelvic sidewall recurrence of endometrial cancer in a patient who has not previously received radiation?

2 Answers available

What is your technique to calculate the vaginal surface dose in gyn intracavitary brachytherapy?

What exactly do you contour and what is your dose constraint to that volume?

4 Answers available

What is the role of parametrial and pelvic side wall boosts in the setting of volumetric brachytherapy for locally advanced cervical cancer treated with either 3DCRT or IMRT?

Does using something like a vienna applicator allow you to avoid dose escalation with more external beam? How do you recommend doing a classic pa...

2 Answers available

What are you posterior field borders for endometrial and cervical cancer 3DCRT plans?

Some classic references recommend the coverage of the entirety of the sacrum but the volume delineation guidelines for both seem to only cover the mos...

1 Answer available

Do the number of lymph nodes removed in a non-Stage IA/FIGO 1 endometrial cancer case, affect your decision for WPRT v. vaginal brachytherapy alone?

1 Answer available

Once endometrial cancer recurs after no chemo or XRT, is it curative or palliative?

Does hydroureter and leg edema alter your opinion?

1 Answer available

What is the best treatment for a medically inoperable endometrial adenocarcinoma of the uterus FIGO 1, grade 1, type 1?

Brachytherapy, EBRT or both and what is the best dose?

1 Answer available

What lessons can we learn from RTOG 0418 in how to best use IMRT to treat endometrial cancer?

1 Answer available

Papers discussed in this category

Gynecologic oncology, 2004-03

A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study.

The New England journal of medicine, 2019-06-13

Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer.

Int. J. Radiat. Oncol. Biol. Phys., 2005-08-01

Intravaginal high-dose-rate brachytherapy for stage I endometrial cancer: a randomized study of two dose-per-fraction levels.

Int. J. Radiat. Oncol. Biol. Phys., 1990-02-01

Postoperative vaginal irradiation with high dose rate afterloading technique in endometrial carcinoma stage I.

Gynecologic oncology, 2003-12

Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases.

Int. J. Radiat. Oncol. Biol. Phys., 2014-05-01

Manifestation pattern of early-late vaginal morbidity after definitive radiation (chemo)therapy and image-guided adaptive brachytherapy for locally advanced cervical cancer: an analysis from the EMBRACE study.

Brachytherapy, 2015

Computed tomography planned interstitial brachytherapy for recurrent gynecologic cancer.

Gynecologic oncology, 2007-11

A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus.

Eur. J. Cancer, 2008 Apr 02

Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874).

J Clin Oncol,

A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study.

Gynecologic oncology, 2018-10

Improved survival with adjuvant brachytherapy in stage IA endometrial cancer of unfavorable histology.

Gynecologic oncology, 2014-11

Neoadjuvant radiotherapy with or without chemotherapy followed by extrafascial hysterectomy for locally advanced endometrial cancer clinically extending to the cervix or parametria.

Lancet, 2010-03-06

Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial.

International journal of radiation oncology, biology, physics, 2018-08-01

Multi-institutional Analysis of Vaginal Brachytherapy Alone for Women With Stage II Endometrial Carcinoma.

Brachytherapy, 2019 Sep - Oct

Vaginal brachytherapy alone for patients with Stage II endometrial cancer with inner half cervical stromal invasion.

Gynecologic oncology, 2009-10

Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-01-01

Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study.

Gynecologic oncology, 2013-10

Risk-scoring system for the individualized prediction of lymphatic dissemination in patients with endometrioid endometrial cancer.

Gynecologic oncology, 2013-01

A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer.

Eur. J. Cancer, 2010 Jul 07

Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-07-20

Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer.

Lancet Oncol., 2019 Jul 22

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial.

Gynecol Oncol, 2019 Sep

Defining the survival benefit of adjuvant pelvic radiotherapy and chemotherapy versus chemotherapy alone in stages III-IVA endometrial carcinoma.

Cancer Nurs, 2017-04-21

Dilator Use After Vaginal Brachytherapy for Endometrial Cancer: A Randomized Feasibility and Adherence Study.

American journal of clinical oncology, 2018-08

Adjuvant External Radiation Impacts Outcome of Pelvis-limited Stage III Endometrial Carcinoma: A Multi-institutional Study.

Cancer, 1987-10-15

Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study.

Gynecologic oncology, 2015-09

Ovarian involvement in endometrioid adenocarcinoma of uterus.

Brachytherapy, 2016 Nov - Dec

Salvage high-dose-rate brachytherapy for isolated vaginal recurrence of endometrial cancer.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2014-10

Definitive salvage for vaginal recurrence of endometrial cancer: the impact of modern intensity-modulated-radiotherapy with image-based HDR brachytherapy and the interplay of the PORTEC 1 risk stratification.

Practical radiation oncology, 2017

Long-term outcomes using adjuvant pelvic intensity modulated radiation therapy (IMRT) for endometrial carcinoma.

Gynecologic oncology, 2018-08

Image-based multichannel vaginal cylinder brachytherapy for the definitive treatment of gynecologic malignancies in the vagina.

International journal of radiation oncology, biology, physics, 2017-04-01

Brachytherapy Improves Survival in Stage III Endometrial Cancer With Cervical Involvement.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-07-10

Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.

Gynecol Oncol, 2017 Aug

Isolated tumor cells identified by sentinel lymph node mapping in endometrial cancer: Does adjuvant treatment matter?

J Gynecol Oncol, 2015 Nov 23

Isolated tumor cells and micrometastases in regional lymph nodes in stage I to II endometrial cancer.

Int J Gynaecol Obstet,

Postirradiation vaginal occlusion: nonoperative management.

Int J Womens Health, 2017 May 02

Radiation-induced vaginal stenosis: current perspectives.

Radiat Oncol, 2015 Feb 22

Modern radiation therapy and potential fertility preservation strategies in patients with cervical cancer undergoing chemoradiation.

Obstet Gynecol,

Treatment of clear cell adenocarcinoma in young females.

Annals of surgical oncology, 2016-05

Low-Volume Lymph Node Metastasis Discovered During Sentinel Lymph Node Mapping for Endometrial Carcinoma.

International journal of radiation oncology, biology, physics, 2014-03-15

Interval between hysterectomy and start of radiation treatment is predictive of recurrence in patients with endometrial carcinoma.

Brachytherapy, 2015

Image-based multichannel vaginal cylinder brachytherapy for vaginal cancer.

Nature, 2013-05-02

Integrated genomic characterization of endometrial carcinoma.

Gynecologic oncology, 2019-09

Comprehensive genomic profiling of recurrent endometrial cancer: Implications for selection of systemic therapy.

F1000Res, 2019 Jun 12

Recent advances in endometrial cancer: a review of key clinical trials from 2015 to 2019.

Lancet Oncol., 2018 Feb 12

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.

Lancet, 2019 Apr 11

Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial.

Gynecol. Oncol., 2019 Sep 26

Contemporary management of uterine clear cell carcinoma: A Society of Gynecologic Oncology (SGO) review and recommendation.

Gynecologic oncology, 2017-08

A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer.

Am J Obstet Gynecol, 2016 Nov 18

Sentinel lymph node assessment in endometrial cancer: a systematic review and meta-analysis.

Eur J Cancer, 2019 Jun 07

Pelvic Sentinel lymph node detection in High-Risk Endometrial Cancer (SHREC-trial)-the final step towards a paradigm shift in surgical staging.

J Clin Med, 2020 Nov 28

Diagnostic Accuracy and Clinical Impact of Sentinel Lymph Node Sampling in Endometrial Cancer at High Risk of Recurrence: A Meta-Analysis.

Int J Gynecol Cancer, 2019 Dec 18

Robotic sentinel lymph node (SLN) mapping in endometrial cancer: SLN symmetry and implications of mapping failure.

Gynecol Oncol, 2019 Jul 22

Lymph node micrometastases and outcome of endometrial cancer.

JAMA oncology, 2016-11-01

Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations.

Gynecologic oncology, 2013-04

Management of uterine adenosarcomas with and without sarcomatous overgrowth.

Gynecologic oncology, 2001-10

Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival.

Lancet, 2008 Dec 16

Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study.

J. Natl. Cancer Inst., 2008 Nov 25

Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial.

Gynecologic oncology, 2019-04

Association of chemotherapy and radiotherapy sequence with overall survival in locoregionally advanced endometrial cancer.

J Gynecol Oncol,

Evaluation of the optimal sequence of adjuvant chemotherapy and radiation therapy in the treatment of advanced endometrial cancer.

Gynecol Oncol, 2020 Aug 15

Adjuvant radiation followed by chemotherapy is associated with improved overall survival in endometrial cancer.

Gynecologic oncology, 2009-10

Prognostic significance and treatment implications of positive peritoneal cytology in endometrial adenocarcinoma: Unraveling a mystery.

Am J Obstet Gynecol, 2017 Dec 06

Prognosis and treatment of positive peritoneal cytology in early endometrial cancer: matched cohort analyses from the National Cancer Database.

Lancet,

Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma.

Journal of minimally invasive gynecology, 2016-02-01

Timing of Intrauterine Manipulator Insertion During Minimally Invasive Surgical Staging and Results of Pelvic Cytology in Endometrial Cancer.

Am J Obstet Gynecol, 2020 Jul 18

Impact of uterine manipulator on oncological outcome in endometrial cancer surgery.

The Lancet. Oncology, 2017-03

A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study.

International journal of radiation oncology, biology, physics, 2004-03-01

Malignant mixed Müllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome.

Gynecologic oncology, 2015-11

A multi-institutional study of outcomes in stage I-III uterine carcinosarcoma.

Gynecol Oncol, 2020 May 29

Executive summary of the American Radium Society® Appropriate Use Criteria for management of uterine carcinosarcoma.

Cancer, 2017-03-01

Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.

Lancet Oncol, 2019 Mar 25

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.

Gynecologic oncology, 2007-06

Outcomes in surgical stage I uterine papillary serous carcinoma.

Int J Gynecol Cancer,

Role of Adjuvant Therapy for Stage IA Serous and Clear Cell Uterine Cancer: Is Observation a Valid Strategy?

Gynecol Oncol Rep, 2020 Jan 30

Dedifferentiated endometrioid adenocarcinoma of the uterus: A case series and review of literature.

World J Surg Oncol, 2017 Jan 10

Dedifferentiated endometrioid carcinoma of the uterus : report of four cases and review of literature.

Gynecologic oncology, 2012-10

High grade undifferentiated uterine sarcoma: surgery, treatment, and survival outcomes.

Practical radiation oncology, 2019

Neoadjuvant Chemoradiation Therapy Followed by Extrafascial Hysterectomy in Locally Advanced Type II Endometrial Cancer Clinically Extending to Cervix.

Brachytherapy, 2019 Apr 17

Magnetic resonance imaging response in patients treated with definitive radiation therapy for medically inoperable endometrial cancer-Does it predict treatment response?

Brachytherapy, 2019

Compendium of fractionation choices for gynecologic HDR brachytherapy-An American Brachytherapy Society Task Group Report.

Radiother Oncol, 2020 Nov 05

Brachytherapy quality assurance in the PORTEC-4a trial for molecular-integrated risk profile guided adjuvant treatment of endometrial cancer.

Pract Radiat Oncol, 2022 Oct 22

Radiation Therapy for Endometrial Cancer: An American Society for Radiation Oncology Clinical Practice Guideline.

Brachytherapy, 2021 Mar 26

Role of brachytherapy in stage III endometrial cancer treated with adjuvant chemotherapy: Identifying factors predictive of a survival benefit.

The American journal of surgical pathology, 2017-01

The Microcystic, Elongated, and Fragmented (MELF) Pattern of Invasion: A Single Institution Report of 464 Consecutive FIGO Grade 1 Endometrial Endometrioid Adenocarcinomas.

Histopathology, 2011 Mar 25

MELF invasion in endometrial cancer as a risk factor for lymph node metastasis.

J Minim Invasive Gynecol, 2021 Feb 08

Hysteroscopic Morcellation in Endometrial Cancer Diagnosis: Increased Risk?

Gynecologic oncology, 2019-06

Low-volume disease in endometrial cancer: The role of micrometastasis and isolated tumor cells.

Gynecol Oncol, 2021 Mar 05

Sentinel lymph node (SLN) isolated tumor cells (ITCs) in otherwise stage I/II endometrioid endometrial cancer: To treat or not to treat?

Brachytherapy, 2020 Dec 29

Do air gaps with image-guided vaginal cuff brachytherapy impact failure rates in patients with high-intermediate risk FIGO Stage I endometrial cancer?

Brachytherapy, 2002

Postoperative intravaginal brachytherapy for endometrial cancer; dosimetric analysis of vaginal colpostats and cylinder applicators.

Gynecologic oncology, 2019-04

Endocrine therapy in endometrial cancer: An old dog with new tricks.

Gynecol Oncol, 2017 Jul 06

Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis.

Cochrane Database Syst Rev, 2011 Jun 15

Adjuvant progestagens for endometrial cancer.

Gynecologic oncology, 2014-05

Implementation and early clinical results utilizing Cs-131 permanent interstitial implants for gynecologic malignancies.

International journal of radiation oncology, biology, physics, 2017-12-01

Reirradiation Using Permanent Interstitial Brachytherapy: A Potentially Durable Technique for Salvaging Recurrent Pelvic Malignancies.

Gynecologic oncology, 2019-03

Outcomes after definitive re-irradiation with 3D brachytherapy with or without external beam radiation therapy for vaginal recurrence of endometrial cancer.

Int J Gynecol Cancer,

Low-volume lymphatic metastasis (isolated tumor cells) in endometrial cancer: management and prognosis.

The Lancet. Oncology, 2014-02

Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004-06-01

Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2004

Role of surgical resection for lung, liver, and central nervous system metastases in patients with gynecological cancer: a literature review.

Arch Gynecol Obstet, 2009 Mar 21

Splenic metastasis from endometrial carcinoma: report of a case and review of literature.

Strahlenther Onkol, 2011 Nov 17

Hematogenous metastases in patients with Stage I or II endometrial carcinoma.

Gynecol Oncol Res Pract, 2016 Jun 17

Surgical management of lung, liver and brain metastases from gynecological cancers: a literature review.

Indian J Med Paediatr Oncol,

Oligometastatic breast cancer: A mini review.

J Clin Oncol, 2020 Sep 29

Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209).

Brachytherapy, 2012

American Brachytherapy Society consensus guidelines for adjuvant vaginal cuff brachytherapy after hysterectomy.

The New England journal of medicine, 2018-11-15

Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2001

Clinical behavior of 203 stage II endometrial cancer cases: the impact of primary surgical approach and of adjuvant radiation therapy.

Int J Gynecol Cancer, 2020 Aug 04

Trends and survival outcomes of robotic, laparoscopic, and open surgery for stage II uterine cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-03-10

Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.

J Clin Oncol, 2019 Nov 04

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.

J Clin Oncol, 2020 Mar 13

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer.

Int J Gynecol Cancer, 2020 Dec 18

ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma.

N Engl J Med, 2022 Jan 19

Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.

Gynecol Oncol, 2020 Nov 05

Uterine serous carcinoma: Molecular features, clinical management, and new and future therapies.

N Engl J Med, 2021 Sep 18

Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.

International journal of radiation oncology, biology, physics, 2013-01-01

The role of vaginal brachytherapy in the treatment of surgical stage I papillary serous or clear cell endometrial cancer.

Cancer, 2009-05-15

Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma.

Gynecologic oncology, 2018-05

The role of adjuvant therapy in stage IA serous and clear cell uterine cancer: A multi-institutional pooled analysis.

Virchows Arch,

ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma.

JAMA, 2014-09-24

Uterine pathology in women undergoing minimally invasive hysterectomy using morcellation.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2008

Management of uterine malignancy found incidentally after supracervical hysterectomy or uterine morcellation for presumed benign disease.

Eur J Obstet Gynecol Reprod Biol, 2021 Nov 16

Intraoperative tumor spill during minimally invasive hysterectomy for endometrial cancer: A survey study on experience and practice.

Eur J Surg Oncol, 2012 Jun 14

Association of breast tumour bed seroma with post-operative complications and late normal tissue toxicity: results from the Cambridge Breast IMRT trial.

Arthritis care & research, 2018-10

Impact of Radiation Therapy on Scleroderma and Cancer Outcomes in Scleroderma Patients With Breast Cancer.

Breast Care (Basel), 2020 Oct 28

Early HER2-Positive Breast Cancer: Current Treatment and Novel Approaches.

Clin Cancer Res, 2020 Jun 29

Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-08-01

Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study.

The Lancet. Oncology, 2015-11

Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.

N Engl J Med, 2021 Feb 13

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.

N Engl J Med, 2015 Apr 19

Pembrolizumab versus Ipilimumab in Advanced Melanoma.

Gynecol Oncol, 2021 May 03

Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer.

Gynecol Oncol, 2019 Oct

Sequencing of therapy in women with stage III endometrial carcinoma receiving adjuvant combination chemotherapy and radiation.

Int J Gynecol Cancer, 2021 Mar 26

Sequencing chemotherapy before radiotherapy for women with stage IIIC endometrial cancer.

J Minim Invasive Gynecol,

Port-site metastasis after laparoscopic surgical staging of endometrial cancer: a systematic review of the published and unpublished data.

J Immunother Cancer, 2022 Jan

Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study.

J Clin Oncol, 2022 Jan 06

Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study.

Int J Gynecol Cancer, 2022 Dec 20

Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program.

J Clin Oncol, 2020 Aug 04

Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy.

Int J Gynecol Cancer, 2020 Oct 12

PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer.

Int J Gynecol Cancer, 2021 Jun

Adjuvant brachytherapy for FIGO stage I serous or clear cell endometrial cancer.

J Contemp Brachytherapy, 2020 Feb 28

The role of vaginal brachytherapy in stage I endometrial serous cancer: a systematic review.

Gynecol Oncol, 2022 Nov 15

Molecular testing for endometrial cancer: An SGO clinical practice statement.

Gynecol Oncol, 2022 Apr 22

Does the addition of radiation improve survival compared to chemotherapy alone in women with stage IV endometrial carcinoma? Analysis of the NCDB and SEER databases.

Int J Gynecol Pathol, 2003 Jul

p16 immunoreactivity may assist in the distinction between endometrial and endocervical adenocarcinoma.

Arch Gynecol Obstet, 1988

CA19-9, CA125 and CEA in endometrial carcinoma tissue and its relation to hormone receptor content and histological grading.

Int J Gynecol Cancer, 2018 May

Tumor Size, an Additional Risk Factor of Local Recurrence in Low-Risk Endometrial Cancer: A Large Multicentric Retrospective Study.

Medicine (Baltimore), 2017 May

Prognostic factors for tumor recurrence in endometrioid endometrial cancer stages IA and IB.

Turk J Med Sci, 2019 Oct 24

Does tumor size have prognostic value in patients undergoing lymphadenectomy in endometrioid-type endometrial cancer confined to the uterine corpus?

Brachytherapy, 2022 Nov 03

What is appropriate target delineation for MRI-based brachytherapy for medically inoperable endometrial cancer?

N Engl J Med, 2023 Mar 27

Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer.

N Engl J Med, 2023 Mar 27

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.

Journal of clinical oncology : Official Journal of the American Society of Clinical Oncology, 2023 Oct 21

Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial.

Gynecologic oncology, 2006-10

Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer.

Int J Gynecol Pathol, 2021 Jul 13

Defining Substantial Lymphovascular Space Invasion in Endometrial Cancer.

Br J Cancer, 2018 Oct 25

Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy.

Int J Radiat Oncol Biol Phys, 2023 Mar 08

Is Substantial Lymphovascular Space Invasion Prognostic in Patients With Pathologically Lymph Node-Negative Endometrial Cancer?

Gynecol Oncol, 2020 Jul 25

Is the risk of substantial LVSI in stage I endometrial cancer similar to PORTEC in the North American population? - A single-institution study.

Translational cancer research, 2021 May

Combination radiation and immunotherapy in gynecologic malignancies-a comprehensive review.

Lancet (London, England), 2023 Oct 20

Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 Oct 23

Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.

Pract Radiat Oncol, 2022 Mar 04

Indications for Adjuvant Radiation Therapy in Patients With pN0(i +) Adenocarcinoma of the Endometrium.

Int J Gynecol Cancer, 2021 Sep 07

ConCerv: a prospective trial of conservative surgery for low-risk early-stage cervical cancer.

J Clin Oncol, 2023 Jan 30

Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study.

Brachytherapy, 2021 Jan 21

Substantial lymphovascular space invasion predicts worse outcomes in early-stage endometrioid endometrial cancer.

Journal of gynecologic oncology, 2020 Nov

Management of stage II endometrial cancer and subsequent oncologic outcomes: a National Cancer Database study.

Mediterranean journal of rheumatology, 2022 Mar 31

Clinical Phenotype and Mechanisms of Leukopenia/Neutropenia in Patients with Primary Sjögren's Syndrome.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 Jul 24

Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer.

Advances in radiation oncology, 2022 Oct 25

Definitive Radiation Therapy for Medically Inoperable Endometrial Carcinoma.

Practical radiation oncology, 2023 Oct 22

Stereotactic Body Radiation Therapy for Gynecologic Malignancies: A Case-Based Radiosurgery Society Practice Review.

European journal of cancer (Oxford, England : 1990), 2015 Jun 03

Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trials.

Annals of oncology : official journal of the European Society for Medical Oncology, 2024 Sep 14

ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer.

Obstetrics and gynecology, 2018 Oct

ACOG Committee Opinion No. 754: The Utility of and Indications for Routine Pelvic Examination.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022 Jul 20

Effectiveness of Intensive Versus Minimalist Follow-Up Regimen on Survival in Patients With Endometrial Cancer (TOTEM Study): A Randomized, Pragmatic, Parallel Group, Multicenter Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022 Oct 06

Surveillance Strategies in Endometrial Cancer Care: Why Less Represents Progress.

Gynecol Oncol, 2021 Feb 1

Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study.

Therapeutic advances in medical oncology, 2024 Sep 28

Safety of dostarlimab in combination with chemotherapy in patients with primary advanced or recurrent endometrial cancer in a phase III, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).

Endometrial Cancer

Questions discussed in this category

Papers discussed in this category

Related Topics